Tissue-Link is developing hemostatic products encompassing a construct of the human protein, tissue factor, as first-in-class.

Tissue-factor initiates and amplifies clot development, and the dressing is able to control excessive life-threatening bleedings.

Tissue-Link methodology circumvent the risk previously known by use of tissue factor as a treatment option.

Studies in minipig have proved promising effect in carotid life-threatening bleeding model.

The team are experienced medical doctors and pharmaceutical industry veterans, and have previously worked with the US Army.